On Thursday, Geron Corp (GERN) stock saw a decline, ending the day at $2.92 which represents a decrease of $-0.09 or -2.99% from the prior close of $3.01. The stock opened at $2.99 and touched a low ...

The last time I wrote about Geron Corporation (NASDAQ:GERN) it was in a Seeking Alpha article entitled “Geron: FDA PDUFA Review With Continued Imetelstat Advancement.” In that article ...

Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Geron (GERN – Research Report), with a price target of $9.00. The company’s shares closed yesterday at $2.94.